drugset / Trial / NCT03776032
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study was to compare the effectiveness of darbopoetin alfa to placebo in the treatment of anemia in adults with lung cancer receiving multicycle platinum-containing chemotherapy, by assessing the percentage of participants who received red blood cell (RBC) transfusions during weeks 5-12 inclusive.
Timeline
- Start
- 1999-09-14
- Primary completion
- 2000-11-08
- Completion
- 2002-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 2.25 ug/kg | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 4.5 ug/kg | Subcutaneous |